A phase II trial of tisagenlecleucel in first-line high-risk HR pediatric and young adult patients with B-cell acute lymphoblastic leukemia B-ALL who are minimal residual disease MRD positive at the end of consolidation EOC therapy

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03876769

Study #:
CMH - CCTL019G2201J

Start Date:
Jul 24, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03876769

View Complete Trial Details & Eligibility at ClinicalTrials.gov